{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:27:40Z","timestamp":1784698060967,"version":"3.55.0"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Arrhythmia"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiac implantable electronic devices (CIED) with reactive atrial\u2010based anti\u2010tachycardia pacing (rATP) have been developed to stop the progression of atrial fibrillation (AF), a frequently occurring arrhythmia. This study assessed the value of rATP from the Australian private healthcare payer perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov state\u2010transition model, including bradycardia, stroke, heart failure (HF), and death, was used to evaluate the value of rATP in conjunction with either pacemakers (PM), implantable cardioverter defibrillators (ICD), cardiac resynchronization therapy pacemakers (CRT\u2010P), or CRT defibrillators (CRT\u2010D). It was assumed that PM patients have bradycardia with no AF, and other patients have mild HF at insertion. Efficacy inputs, battery life, and device costs varied between devices. Conservatively, outpatient\/follow\u2010up costs of stroke and HF were excluded. All analyses were conducted using a cost\u2010effectiveness threshold of 50\u2009000 Australian dollars (A$) per quality\u2010adjusted life year (QALY) gained, and deterministic sensitivity analysis was performed on key inputs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Using a 30\u2010year horizon and a 5% discount rate, rATP was cost\u2010effective up to a value of A$5609 (PM), A$11\u2009628 (CRT\u2010D), A$14\u2009142 (CRT\u2010P), and A$17\u2009858 (ICD). In sensitivity analysis, varying patient age, rATP efficacy, HF and stroke mortality, stroke recurrence risk, utility values, time horizon, battery life, and the discount rate, the value of rATP ranged from A$3122 to A$11\u2009375 (PM), A$1455 to A$26\u2009409 (ICD), A$1171 to A$20\u2009674 (CRT\u2010P), and A$973 to A$16\u2009907 (CRT\u2010D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Reactive ATP provides clinical benefits to patients who require a CIED. These benefits justify a value premium for devices with rATP functionality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/joa3.70043","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T10:49:34Z","timestamp":1745405374000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost\u2010effectiveness analyses to assess the value of reactive atrial\u2010based anti\u2010tachycardia pacing for patients with pacemakers and defibrillators: An Australian private healthcare system perspective"],"prefix":"10.1002","volume":"41","author":[{"given":"Adam","family":"Gordois","sequence":"first","affiliation":[{"name":"Fortrea  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Medtronic Japan Co., Ltd  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiro","family":"Uenishi","sequence":"additional","affiliation":[{"name":"Medilead., Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Medilead., Inc.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Shoji","sequence":"additional","affiliation":[{"name":"Healthcare Consulting Inc.  Fujimi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4217-4836","authenticated-orcid":false,"given":"Michelle","family":"Hill","sequence":"additional","affiliation":[{"name":"Medtronic Australasia Pty Ltd  North Ryde New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Atrial fibrillation in Australia","author":"Australian Institute of Health and Welfare (AIHW)","year":"2020"},{"key":"e_1_2_9_3_1","volume-title":"General practice insights report July 2020\u2013June 2021","author":"National Prescribing Service (NPS) MedicineWise","year":"2021"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"e_1_2_9_5_1","volume-title":"Disease expenditure in Australia 2019\u201320","author":"Australian Institute of Health and Welfare (AIHW)","year":"2022"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx042"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105575"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euab232"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu165"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euy286"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2015.04.015"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2019.10.001"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2015.02.017"},{"key":"e_1_2_9_14_1","volume-title":"Quarterly private health insurance statistics March 2023","author":"Australian Prudential Regulation Authority (APRA)","year":"2023"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euad003"},{"key":"e_1_2_9_16_1","volume-title":"Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee (Version 5.0)","author":"Australian Government Department of Health","year":"2016"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14704"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010869"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.03.519"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009540"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2014.08.019"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032423"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.121.038155"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2018.01.009"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja16.00525"},{"key":"e_1_2_9_26_1","volume-title":"Life tables, states, territories and Australia\u20142019\u20132021","author":"Australian Bureau of Statistics (ABS)","year":"2022"},{"key":"e_1_2_9_27_1","volume-title":"Azure\u2122 Pacemaker with BlueSync\u2122 Technology product brochure","author":"Medtronic","year":"2020"},{"key":"e_1_2_9_28_1","volume-title":"Cobalt\u2122 XT ICD and CRT\u2010D product brochure","author":"Medtronic","year":"2020"},{"key":"e_1_2_9_29_1","volume-title":"Percepta\u2122 Quad CRT\u2010P MRI SureScan\u2122 product brochure","author":"Medtronic","year":"2020"},{"key":"e_1_2_9_30_1","volume-title":"Prostheses list effective 1 July 2023","author":"Australian Government Department of Health and Aged Care","year":"2023"},{"key":"e_1_2_9_31_1","volume-title":"Private hospital data bureau annual report 2021\u20132022","author":"Australian Government Department of Health and Aged Care","year":"2022"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-014-0676-x"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024296"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.11.030"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100676"}],"container-title":["Journal of Arrhythmia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/joa3.70043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T14:57:45Z","timestamp":1764169065000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/joa3.70043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/joa3.70043"],"URL":"https:\/\/doi.org\/10.1002\/joa3.70043","archive":["Portico"],"relation":{},"ISSN":["1880-4276","1883-2148"],"issn-type":[{"value":"1880-4276","type":"print"},{"value":"1883-2148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-10-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70043"}}